I’rom Holdings Co. Ltd., Minerva Biotechnologies deal

The ID Pharma Co. Ltd. subsidiary of I’rom granted Minerva worldwide rights to use and commercialize Sendai virus vectors to generate human induced pluripotent stem (iPS) cells. Minerva will use the v...